Non-Selective β-Blocker Use and Portal Vein Thrombosis in Cirrhosis: An Updated Systematic Review and Meta-Analysis
Related Experiment Video
Updated: Sep 27, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Sanchuan Lai1, Wei Wei1, Tingting Su2
1Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Abstract:
Background/Objectives: The association between non-selective β-blocker (NSBB) use and portal vein thrombosis (PVT) in patients with cirrhosis remains controversial. Prior meta-analyses had notable methodological limitations and may have overestimated this relationship. This updated systematic review and meta-analysis aimed to comprehensively evaluate the association between NSBB therapy and PVT risk in cirrhotic populations. Methods: We systematically searched PubMed, Web of Science, the Cochrane Library, and EMBASE up to 24 January 2026. Observational clinical studies comparing PVT incidence between cirrhotic patients receiving NSBBs and those not receiving NSBB treatment were included. The Newcastle-Ottawa Scale (NOS) was used for methodological quality assessment. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated separately using random-effects models. Subgroup, sensitivity, and publication bias analyses were performed to explore heterogeneity and verify result robustness. Results: Eighteen observational studies enrolling 8104 cirrhotic patients were finally included. For binary PVT endpoints from 12 studies, NSBB use was significantly associated with elevated PVT risk (pooled OR = 1.89, 95% CI 1.29-2.78), with moderate-to-high between-study heterogeneity (I2 = 67.8%). For longitudinal incident PVT evaluated by HRs in 6 cohort studies, the overall pooled association did not reach statistical significance (HR = 1.61, 95% CI 0.99-2.63). Subgroup analyses demonstrated that the effect size was further attenuated after multivariable adjustment. Conclusions: Observational evidence reveals a correlation between NSBB exposure and higher PVT prevalence in cirrhotic patients. However, adjusted longitudinal data fail to confirm that NSBB therapy independently increases the risk of de novo PVT. Large-scale, well-adjusted prospective cohort studies are needed to verify the relationship between NSBB administration and incident PVT.
Related Concept Videos
Portal Hypertension
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Esophageal Varices-I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

